Los Angeles, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Triller Group Inc. (Nasdaq: ILLR) (“Triller Group”, or “the Company”) announced today that the Nasdaq Hearings Panel has granted an extension period for the Company to regain compliance with its listing requirements on The Nasdaq Stock Market. Following a hearing held on November 25, 2025, the Panel has granted Triller an exception period subject to the Company satisfying the following conditions: File its 2024 Form 10-K and delinquent Forms 10-Q for the quarte ...

Continued listing reflects progress on turnaround strategy and pipeline advancementBURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements. “We view this extension as a recogni ...

Highlights: Eloro's second phase definition diamond drilling program has now been completed with sixteen (16) drill holes drilled totalling 8,286.40 metres across the potential starter pit area (1,000m by 600m by 500m deep). The program has succeeded in confirming continuity and expanding higher-grade silver-tin-polymetallic mineralization in this extensive porphyry-epithermal system. DSB-93, an infill hole drilled 107m northeast of discovery hole DSB-61, intersected the highest silver interval obtained thu ...

24‑hour operation achieved; optimization advancing toward ~92% gold recoveryVANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (TSXV: ASE | GSE: ASG | OTCQX: ASGOF) ("Asante" or the "Company") is pleased to provide an update on the ramp‑up of the new sulphide treatment plant (“STP”) at the Bibiani Gold Mine (“Bibiani”) in Ghana. Highlights Ramp‑up: Construction and commissioning are complete. Plant operations began on a 12‑hour basis on September 27, 2025, with continuou ...

– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest in Addressing the Burden of Hearing Loss Among Patients Receiving Cisplatin-Based Chemotherapy – RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the planned initiation of an investigator-sponsored stu ...

Core Insights - Tonix Pharmaceuticals has appointed Irina Ishak as General Counsel, effective December 8, 2025, bringing over 25 years of experience in corporate legal and strategic leadership within the life sciences industry [1][2] - The company is focused on commercializing its marketed products and advancing its pipeline, with Ishak's expertise expected to be a significant asset in these efforts [2][3] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a development pipeline [4] - The company markets TONMYA™, the first FDA-approved therapy for fibromyalgia in over 15 years, along with treatments for acute migraine [4] - Tonix's development portfolio targets central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4] Recent Developments - The company has recently launched TONMYA™, which is a non-opioid analgesic for fibromyalgia, and is expanding its research into other conditions [3][4] - Tonix is also developing TNX-102 SL for acute stress reaction and major depressive disorder, and has a contract with the U.S. Department of Defense for TNX-4200, a broad-spectrum antiviral agent [4]

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp.” or the “Company”), a leading critical minerals mining company, today announced that it has executed the Term-Sheet for creating a 50%-50% joint venture (JV) between CRML and Fabrica de Prelucrare a Concentratelor de Uraniu S.R.L. (FPCU) of Romania, a state-owned entity and a strategic partner from a European Union and NATO member country. The term sheet provides CRML with long-term offtake rights for 50 ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence Bio ...

Strengthens Aeluma’s Heterogeneous Integration Platform and Expands Intellectual Property Portfolio to 35 Issued and Pending PatentsGOLETA, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today that it has filed a new patent application, expanding its intellectual property portfolio to 35 issued and pending patents. ...

Core Viewpoint - Ligand Pharmaceuticals is hosting its Investor Day to present its strategy, investment activities, royalty portfolio, and long-term financial outlook, highlighting a strong business outlook and advancements in its royalty portfolio [1][2]. Financial Overview and Outlook - Ligand reiterates its 2025 guidance and introduces its 2026 guidance, projecting full-year revenue of $245 million to $285 million, which represents an approximately 15% increase in core revenue growth over 2025 [3]. - The company expects royalty revenue to be between $200 million and $225 million, indicating a 40% increase over 2025, with core adjusted earnings per diluted share projected at $8.00 to $9.00 [3]. - A five-year outlook anticipates a compound annual growth rate (CAGR) of at least 23% for royalty receipts, driven by products like Filspari, Ohtuvayre, and Zelsuvmi [3][4]. Key Financial Performance - In 2025, Ligand's financial performance is expected to show a 40% increase in royalty revenue and a 30% increase in core adjusted earnings per share [4]. - Total core revenue is projected to be between $225 million and $235 million, with royalty revenue contributing $147 million to $157 million, alongside $40 million in Captisol sales and $38 million in core contract revenue [4]. Investment Activity - The company committed $130 million across six investments in 2025, with a robust pipeline heading into 2026 [4]. - Ligand has $1 billion in deployable capital aimed at driving long-term royalty revenue growth through disciplined allocation [4]. Royalty Revenue Drivers - Key drivers for royalty revenue in 2026 include Filspari (Travere Therapeutics), Ohtuvayre (Merck), Capvaxive (Merck), Qarziba (Recordati S.p.A.), and Zelsuvmi (Pelthos Therapeutics) [4]. Business Model and Technology Platforms - Ligand operates a business model focused on generating value through a diversified portfolio of biotech and pharmaceutical product revenue streams, supported by an efficient corporate cost structure [7]. - The company utilizes royalty-generating technology platforms, including Captisol® and NITRICIL™, which are designed to optimize drug solubility and stability, and facilitate tunable dosing, respectively [7].